The writer argues GLP-1 buzz risks drowning out the case for treating obesity as a long-term disease with individualized care.
Recap by typeshit. Post by Facebook on Facebook.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
Dr. Nadolsky responds to a clip from comedian @stavvybaby2 about GLP-1s, adding a doctor's view to the joke.
He calls GLP-1 drugs useful before surgery or after regain, but says surgery stays the main option for people who need large, lasting weight loss.
An anonymous poster says people put their dramatic weight loss down to their mother's death, when it was really Ozempic they wanted to keep quiet.
The author says they searched the phase three results for a catch and found none, and explains why the strong numbers still worry them.
The author went hunting for a catch in the phase 3 numbers and says none turned up, while admitting the results made them uneasy.
Loading…